- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06415669
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
May 26, 2024 updated by: Mingquan Cai, The First Affiliated Hospital of Xiamen University
A Study of Paclitaxel (Albumin-bound) Combined With Apatinib and Adebrelimab in the Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma Following Previous Immunotherapy Progression
To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mingquan Cai
- Phone Number: 13696908231
- Email: mingquan035@163.com
Study Locations
-
-
Fujian
-
Fuzhou, Fujian, China
- Recruiting
- The First Affiliated Hospital of Xiamen University
-
Contact:
- Mingquan Cai
- Phone Number: 13696908231
- Email: mingquan035@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 1) Age: 18 ~ 75 years old, male and female;
- 2) ECOG score: 0 or 1;
- 3) Patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction adenocarcinoma confirmed by histopathology;
- 4) Patients who have received at least first-line immunotherapy progression or intolerance in the past, and the number of previous systemic treatment lines does not exceed 2 lines; The best curative effect of frontline containing PD-1/PD-L1 was CR, PR or SD;
- 5) According to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1), there should be at least one measurable lesion that has not received local treatment such as radiotherapy (lesions located in the area of previous radiotherapy can also be selected as target lesions if progression is confirmed);
- 6) The major organs function normally and meet the following criteria
- a. In the past 14 days without the use of granulocyte colony-stimulating factor, the absolute value of neutrophil (ANC) ≥1.5x109 /L;
- b. Platelets ≥100×109 /L in the past 14 days without blood transfusion;
- c. Hemoglobin >90g/L in the last 14 days without blood transfusion or use of erythropoietin;
- d. Total bilirubin ≤1.5× upper limit of normal (ULN);
e. aspartate aminotransferase (AST), alanine aminotransferase (ALT) in
≤2.5×ULN (ALT or AST ≤5×ULN for patients with liver metastasis);
- f. Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥40 ml/min;
- g. Good coagulation function, defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN;
- h. The myocardial enzyme profile is within the normal range (if the researchers comprehensively judge that the simple laboratory abnormality is not clinically significant, it is also allowed to be included);
- 7) Expected survival ≥3 months;
- 8) Women of reproductive age should agree to use contraceptives (such as Iuds, contraceptives, or condoms) during the study period and for 6 months after the study ends; Have a negative serum or urine pregnancy test within 7 days prior to study enrollment and must be a non-lactating patient; Men should consent to patients who must use contraception during the study period and for 6 months after the end of the study period;
- 9) Sign informed consent.
Exclusion Criteria:
- 1) Patients who have previously received paclitaxel chemotherapy; Patients with neoadjuvant or adjuvant treatment with taxoid drugs and disease progression more than 6 months after the last chemotherapy were excluded;
- 2) HER2-positive patients;
- 3) Patients who are taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes (dose >10mg/ day prednisone or other therapeutic hormone) and continue to use within 2 weeks before enrollment;
- 4) Patients with severe liver and kidney insufficiency or heart insufficiency;
- 5) have multiple factors that affect oral drugs (such as inability to swallow, gastrointestinal resection, chronic diarrhea, and intestinal obstruction);
- 6) Patients with brain metastases accompanied by symptoms or symptom control for less than 3 months;
- 7) Patients who are known to be allergic to any investigational drug or drug excipient;
- 8) Pregnant or lactating female patients;
- 9) Patients who underwent major surgical procedures (craniotomy, thoracotomy, or laparotomy) or had unhealed surgical wounds, ulcers, or fractures within 4 weeks prior to initial dosing, except for patients ≥2 weeks after surgery and patients with old fractures that the investigator determined could be treated with the study drug;
- 10) Patients with moderate to severe ascites accompanied by clinical symptoms requiring repeated drainage; Patients with uncontrolled or clinical symptoms of pleural effusion or pericardial effusion;
- 11) Patients with clinically significant electrolyte disorders;
- 12) People with acute or chronic active hepatitis B or hepatitis C: hepatitis B virus (HBV) DNA > 2000IU/ml or 104 copies /ml; Hepatitis C virus (HCV) RNA > 103 copies /ml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibody positive patients;
- 13) Patients with central nervous system metastasis, but with no clinical symptoms or accompanied by clinical symptoms after treatment, disease control and stable time ≥4 weeks can be enrolled; To meet the need for measurable lesions outside the central nervous system, hormone therapy should be discontinued 14 days before the first study of medication
- 14) Any life-threatening bleeding event within the previous 3 months, including patients requiring transfusion therapy, surgery or local therapy, and ongoing medication;
- 15) Patients with a history of arteriovenous thromboembolism events, including myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or any other severe thromboembolism within the past 6 months. The exception is implantable intravenous infusion port or catheter-derived thrombosis, or superficial venous thrombosis, which is stable after conventional anticoagulant therapy. Allow patients to prophylactically use small doses of low molecular weight heparin (e.g., enoxaparin 40 mg/ day);
- 16) Uncontrolled hypertension, systolic blood pressure > 160 MMHG or diastolic blood pressure > 100mmHg after optimal medical treatment, hypertensive crisis or hypertensive encephalopathy history;
- 17) Symptomatic congestive heart failure (New York Heart Association Grade II-IV). Symptomatic or poorly controlled arrhythmia. Patients with a history of congenital long QT syndrome or a QTc > 500ms (calculated using the Fridericia method) corrected at screening;
- 18) For patients who received radiation therapy more than 4 weeks before the first treatment, all of the following conditions must be met to be enrolled: there is no current toxic reaction related to radiation therapy, no need to take glucocorticoids, and radiation pneumonia, radiation hepatitis, and radiation enteritis are excluded;
- 19) Patients with previous or current pulmonary diseases such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, and severe impairment of lung function;
- 20) Human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive), known syphilis infection;
- 21) Patients with unhealed wounds, fractures, gastric and duodenal ulcers, persistent positive stool occultiblood, ulcerative colitis, or other conditions that researchers have determined may cause gastrointestinal bleeding or perforation;
- 22) All adverse events during the screening period have not returned to baseline or ≤ Grade 1 (NCI-CTCAE V5.0) (except for alopecia, or peripheral sensory neuropathy, which can be grade 2);
- 23) Patients with severe infections that are active or poorly controlled clinically. Patients with severe infections in the 4 weeks prior to initial dosing, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia;
- 24) Use of immunosuppressive drugs within 4 weeks prior to initial administration, excluding nasal, inhaled, or other routes of topical corticosteroids or physiological doses of systemic corticosteroids (i.e., no more than 10mg/ day of prednisone or equivalent doses of other corticosteroids); To allow temporary use of glucocorticoids for the treatment of breathing difficulties in diseases such as asthma and chronic obstructive pulmonary disease;
- 25) Patients who received live attenuated vaccine within 4 weeks prior to initial administration or who planned to receive live attenuated vaccine during the study period;
- 26) Patients who received major surgical treatment or significant traumatic injury 4 weeks prior to initial dosing
- 27) Patients who received traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose;
- 28) Patients with a history of gastrointestinal perforation or abscess within 6 months prior to enrollment;
- 29) Received treatment in other clinical trials within 4 weeks prior to initial dosing;
- 30) Patients whose urine routine indicated urinary protein ≥2+, or 24-hour urinary protein quantity >1.0g;
- 31) The presence of any active autoimmune disease or history of autoimmune disease (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis); Patients with asthma requiring medical intervention with bronchodilators were not included); However, the following patients were admitted: vitiligo, psoriasis, alopecia, well-controlled type I diabetes without systemic therapy, hypothyroidism with normal thyroid function treated by replacement therapy;
- 32) Other acute or chronic medical conditions, psychiatric disorders, or abnormalities in laboratory test values that may contribute to these results: increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results, and, in the investigator's judgment, classify patients as ineligible to participate in the study;
- 33) Other situations deemed unsuitable for inclusion by the researcher.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
Paclitaxel for injection (albumin-bound) in combination with Apatinib mesylate and adebrelimab
|
100 mg/m2, day 1, day 8, every 21 days for a cycle.
20mg/kg or 1200mg, the first day, every 21 days as a cycle.
Other Names:
250mg once a day for 5 consecutive days and discontinue for 2 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate(ORR)
Time Frame: 1 years
|
Refers to the proportion of all subjects with the best overall response (BOR) as complete remission (CR) or partial remission (PR) according to RECIST 1.1 criteria.
|
1 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate(DCR)
Time Frame: 1 years
|
Refers to the proportion of all subjects with the best overall response (BOR) according to RECIST1.1 criteria as complete remission (CR), partial remission (PR) and stable disease (SD).
|
1 years
|
Progression-free survival (PFS)
Time Frame: 1 years
|
PFS was defined as the subject's date from the date of the first dose to the date of the first documented tumor progression (as assessed by RECIST1.1 criteria, with or without continuation of treatment) or the date of death from any cause, whichever occurred first.
|
1 years
|
Duration of response (DoR) Duration of response (DoR) Duration of response (DoR) Duration of response (DoR) Duration of response (DoR) Duration of response (DoR)
Time Frame: 1 years
|
It refers to the time between the first evaluation of a tumor as CR or PR and the second evaluation as Progressive Disease (PD) or death from any cause.
|
1 years
|
Overall survival(OS)
Time Frame: 2 years
|
Defined as the time from the date of the first dose to the death of the subject from any cause.
|
2 years
|
Occurence of AE and SAE
Time Frame: 2 years
|
Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0)
|
2 years
|
Appraisal of life quality
Time Frame: 1 years
|
Quality of life scale for cancer patients(The EORTC's QLQ-C30 (V3.0)) is a core scale for all cancer patients with 30 entries.Items 29 and 30 are divided into seven grades, ranging from 1 to 7 according to their answer choices; Other items are rated on a four-point scale,with a straightforward scale of 1 to 4.Except for items 29 and 30, they are all reverse entries (the larger the value, the worse the quality of life).The score for each field is obtained by adding and dividing the scores for the items included in each field by the number of items included (RS).The standard component of the computing function area also changes direction.
Specifically, it is calculated according to the following formula (where R is the score range of each field or item).Functional area: SS=[1-(RS-1)/R]*100 Symptom domain and general health status domain :SS=[(RS-1)/R]*100
|
1 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explore potential biomarkers in tumor tissue
Time Frame: 1 years
|
ORR corresponding to PD-L1 negative expression, positive expression (TPS≥1%), low expression (<10%), high expression (TPS>50%)
|
1 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mingquan Cai, The First Affiliated Hospital of Xiamen University
- Principal Investigator: Xia Lv, Xiamen Hongai Hospital
- Principal Investigator: Jun Qiu, Xiamen Hongai Hospital
- Principal Investigator: Huita Wu, Zhongshan Hospital Affiliated to Xiamen University
- Principal Investigator: Xiuping Zhang, Zhongshan Hospital (Xiamen), Fudan University
- Principal Investigator: Xiaojian Yin, Xiamen Changgeng Hospital
- Principal Investigator: Jinfeng Zhu, Quanzhou First Hospital
- Principal Investigator: Yijun Wang, Zhangzhou Hospital
- Principal Investigator: Guoqin Qiu, The 73rd Army Hospital
- Principal Investigator: Wen Chen, The Second Affiliated Hospital of Fujian Medical University
- Principal Investigator: Yongmei Liu, West China Xiamen Hospital of Sichuan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 19, 2024
Primary Completion (Estimated)
May 19, 2026
Study Completion (Estimated)
May 19, 2027
Study Registration Dates
First Submitted
April 27, 2024
First Submitted That Met QC Criteria
May 10, 2024
First Posted (Actual)
May 16, 2024
Study Record Updates
Last Update Posted (Actual)
May 29, 2024
Last Update Submitted That Met QC Criteria
May 26, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Adenocarcinoma
- Esophageal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Protein Kinase Inhibitors
- Paclitaxel
- Apatinib
Other Study ID Numbers
- 23-OBU-FJ-GC-II-013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric/Gastroesophageal Junction Adenocarcinoma
-
M.D. Anderson Cancer CenterRecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedClinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage 0 Gastric... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingPeritoneal Carcinomatosis | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
-
National Cancer Institute (NCI)Active, not recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); IpsenWithdrawnGastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric AdenocarcinomaUnited States
Clinical Trials on Paclitaxel for injection (albumin-bound)
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.UnknownNon-Small Cell Lung CancerChina
-
China Medical University, ChinaRecruiting
-
Peking UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingGastric Cancer | Adenocarcinoma of Esophagogastric JunctionChina
-
Sun Yat-sen UniversityShanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.RecruitingEsophageal Small Cell CarcinomaChina
-
Fuzhou General HospitalUnknownNasopharyngeal CarcinomaChina
-
Peking University Third HospitalJilin Provincial Tumor Hospital; Affiliated Hospital of Hebei University; Hebei...Not yet recruiting
-
Nanfang Hospital, Southern Medical UniversityNot yet recruitingNeoadjuvant Therapy | Esophageal Carcinoma
-
Shanghai Yizhong Pharmaceutical Co., Ltd.RecruitingMetastatic Breast Cancer (MBC)China
-
Guangzhou Institute of Respiratory DiseaseJiangsu HengRui Medicine Co., Ltd.; BGI-ShenzhenCompletedEsophageal Squamous Cell Carcinoma | ImmunotherapyChina
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina